Loading...
XHEL
BIOBV
Market cap45mUSD
May 23, Last price  
2.79EUR
1D
7.31%
1Q
-9.12%
Jan 2017
-53.88%
Name

Biohit Oyj

Chart & Performance

D1W1MN
P/E
15.24
P/S
2.77
EPS
0.18
Div Yield, %
—
Shrs. gr., 5y
0.21%
Rev. gr., 5y
7.30%
Revenues
14m
+9.36%
28,660,00031,408,00032,751,00034,805,00035,366,00040,044,00039,922,0002,048,0003,452,0004,363,0006,051,0008,195,0008,979,0009,931,00010,052,0007,123,0009,361,00010,951,00013,076,00014,300,000
Net income
3m
+40.46%
-226,000-839,000-1,502,000897,000387,00061,00037,710,000-3,656,000-5,917,000-1,161,000-2,917,000-3,295,0006,139,000-2,143,000-1,416,000-3,312,000-1,500,000601,0001,851,0002,600,000
CFO
600k
-33.48%
605,000100,0001,040,0001,188,0002,796,0001,961,0004,957,000-8,890,000-4,443,000-3,435,000-3,147,000-2,457,000-943,000-93,00083,000-25,000-444,0001,848,000902,000600,000
Dividend
Apr 15, 20140.7234 EUR/sh
Earnings
Jun 05, 2025

Profile

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.
URL
https://www.biohithealthcare.com/
IPO date
Jun 18, 1999
Employees
42
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14,300
9.36%
13,076
19.40%
10,951
16.99%
Cost of revenue
5,000
10,052
6,534
Unusual Expense (Income)
NOPBT
9,300
3,024
4,417
NOPBT Margin
65.03%
23.13%
40.33%
Operating Taxes
300
344
267
Tax Rate
3.23%
11.38%
6.04%
NOPAT
9,000
2,680
4,150
Net income
2,600
40.46%
1,851
207.99%
601
-140.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
100
68
BB yield
-0.29%
-0.24%
Debt
Debt current
300
275
257
Long-term debt
900
1,129
1,629
Deferred revenue
Other long-term liabilities
7
7
Net debt
(2,600)
(5,528)
(294)
Cash flow
Cash from operating activities
600
902
1,848
CAPEX
(400)
(248)
(59)
Cash from investing activities
100
192
(625)
Cash from financing activities
(200)
(199)
(186)
FCF
9,702
1,752
3,482
Balance
Cash
6,700
6,814
6,227
Long term investments
(2,900)
118
(4,047)
Excess cash
3,085
6,278
1,632
Stockholders' equity
8,900
9,425
7,457
Invested Capital
9,815
3,856
6,636
ROIC
131.67%
51.09%
62.45%
ROCE
72.66%
29.83%
53.40%
EV
Common stock shares outstanding
15,163
15,127
15,065
Price
2.29
21.16%
1.89
20.38%
1.57
-14.44%
Market cap
34,724
21.45%
28,591
20.88%
23,653
-14.33%
EV
32,124
23,063
23,359
EBITDA
9,600
3,387
4,897
EV/EBITDA
3.35
6.81
4.77
Interest
300
223
34
Interest/NOPBT
3.23%
7.37%
0.77%